AUPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AUPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-26), Aurinia Pharmaceuticals's current share price is $5.21. Aurinia Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.48. Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 10.85.
The historical rank and industry rank for Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Aurinia Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 84.82. The lowest was 0.79. And the median was 8.62.
AUPH's Cyclically Adjusted PS Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Aurinia Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.349. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.48 for the trailing ten years ended in Mar. 2024.
The historical data trend for Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 36.24 | 28.27 | 19.67 | 21.03 | 10.45 |
For the Biotechnology subindustry, Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 5.21 | / | 0.48 | |
= | 10.85 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Aurinia Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.349 | / | 126.2576 | * | 126.2576 | |
= | 0.349 |
Current CPI (Mar. 2024) = 126.2576.
Aurinia Pharmaceuticals Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.002 | 99.473 | 0.003 |
201409 | 0.002 | 99.394 | 0.003 |
201412 | 0.002 | 98.367 | 0.003 |
201503 | 0.002 | 99.789 | 0.003 |
201506 | 0.002 | 100.500 | 0.003 |
201509 | 0.002 | 100.421 | 0.003 |
201512 | 0.002 | 99.947 | 0.003 |
201603 | 0.002 | 101.054 | 0.002 |
201606 | 0.002 | 102.002 | 0.002 |
201609 | 0.001 | 101.765 | 0.001 |
201612 | 0.001 | 101.449 | 0.001 |
201703 | 0.001 | 102.634 | 0.001 |
201706 | 0.004 | 103.029 | 0.005 |
201709 | 0.000 | 103.345 | 0.000 |
201712 | 0.000 | 103.345 | 0.000 |
201803 | 0.000 | 105.004 | 0.000 |
201806 | 0.000 | 105.557 | 0.000 |
201809 | 0.004 | 105.636 | 0.005 |
201812 | 0.000 | 105.399 | 0.000 |
201903 | 0.000 | 106.979 | 0.000 |
201906 | 0.000 | 107.690 | 0.000 |
201909 | 0.002 | 107.611 | 0.002 |
201912 | 0.000 | 107.769 | 0.000 |
202003 | 0.000 | 107.927 | 0.000 |
202006 | 0.000 | 108.401 | 0.000 |
202009 | 0.000 | 108.164 | 0.000 |
202012 | 0.395 | 108.559 | 0.459 |
202103 | 0.007 | 110.298 | 0.008 |
202106 | 0.052 | 111.720 | 0.059 |
202109 | 0.114 | 112.905 | 0.127 |
202112 | 0.176 | 113.774 | 0.195 |
202203 | 0.153 | 117.646 | 0.164 |
202206 | 0.199 | 120.806 | 0.208 |
202209 | 0.393 | 120.648 | 0.411 |
202212 | 0.200 | 120.964 | 0.209 |
202303 | 0.241 | 122.702 | 0.248 |
202306 | 0.291 | 124.203 | 0.296 |
202309 | 0.382 | 125.230 | 0.385 |
202312 | 0.314 | 125.072 | 0.317 |
202403 | 0.349 | 126.258 | 0.349 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert T Foster | director | C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837 |
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Jeffrey Allen Bailey | director | BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612 |
R. Hector Mackay-dunn | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
Jayne David R.w. | director | #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8 |
Jill Leversage | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
Daniel Billen | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
Joseph P Hagan | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
Brinda Balakrishnan | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
Peter Greenleaf | director, officer: Chief Executive Officer | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Joseph M Miller | officer: Chief Financial Officer | C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Stephen P. Robertson | officer: EVP, General Counsel | #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8 |
Milne George M Jr | director | |
Matthew Maxwell Donley | officer: Ex VP, Intern'l Operations | 4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814 |
Scott Michael Habig | officer: Chief Commercial Officer | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
From GuruFocus
By Business Wire • 08-21-2023
By Business Wire • 10-19-2023
By Business Wire • 09-21-2023
By Business Wire • 06-29-2023
By Business Wire • 12-20-2023
By Business Wire Business Wire • 05-02-2023
By Business Wire Business Wire • 05-17-2023
By Business Wire • 08-03-2023
By Business Wire Business Wire • 01-25-2023
By Business Wire • 11-02-2023